Kelly, R. J., Force, J., Rajan, A., Keen, C., Turkbey, B., Cao, L., … Giaccone, G. (2010). Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). In Journal of Clinical Oncology (Vol. 28, pp. 7626–7626). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2010.28.15_suppl.7626

Kelly, R. J., J. Force, A. Rajan, C. Keen, B. Turkbey, L. Cao, M. Raffeld, S. M. Steinberg, J. J. Wright, and G. Giaccone. “Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).” In Journal of Clinical Oncology, 28:7626–7626. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.7626.

Kelly RJ, Force J, Rajan A, Keen C, Turkbey B, Cao L, et al. Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 7626–7626.

Kelly, R. J., et al. “Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2010, pp. 7626–7626. Crossref, doi:10.1200/jco.2010.28.15_suppl.7626.

Kelly RJ, Force J, Rajan A, Keen C, Turkbey B, Cao L, Raffeld M, Steinberg SM, Wright JJ, Giaccone G. Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010. p. 7626–7626.